Physician profile
David E Pallares
NPI 1023082484
$22,217.43
in general payments reported to CMS, 2019-2025
47 companies · $3,319 in 2025
The $3,319 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,664 · 2020: $1,775 · 2021: $4,182 · 2022: $3,613 · 2023: $3,471 · 2024: $3,193 · 2025: $3,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,679 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,679.31 |
| Education | $304.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,452.82 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $3,047.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $2,576.09 | 2019-2025 | Dupixent |
| Csl Behring | $1,435.14 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $875.24 | 2019-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Novo Nordisk INC | $782.05 | 2019-2024 | |
| Pfizer INC. | $724.14 | 2020-2025 | |
| Genzyme Corporation | $697.60 | 2022-2025 | |
| Genentech USA, INC. | $606.33 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $524.47 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Abbvie INC. | $521.25 | 2021-2022 | |
| Kaleo, INC. | $437.00 | 2019-2024 | Auvi-Q |
| Amgen INC. | $430.55 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $421.08 | 2019-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $297.19 | 2019-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $294.89 | 2021-2023 | Opzelura |
| Alk-Abello, INC | $276.23 | 2019-2022 | |
| Lilly USA, LLC | $272.39 | 2019-2025 | Ebglyss |
| Grifols USA, LLC | $220.91 | 2021-2024 | Xembify |
| Allergan, INC. | $220.31 | 2019 | |
| Pharming Healthcare, INC. | $180.62 | 2020-2025 | Ruconest |
| Optinose US, INC. | $180.08 | 2019-2023 | |
| Shire North American Group INC | $173.04 | 2019 | |
| Biocryst US Sales Co., LLC | $162.55 | 2021-2025 | Orladeyo |
| Galderma Laboratories, L.P. | $154.67 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $152.98 | 2024 | |
| Sanofi US Services INC. | $134.33 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $127.46 | 2021 | |
| Merck Sharp & Dohme LLC | $126.99 | 2023-2025 | Capvaxive |
| Horizon Therapeutics Plc | $114.21 | 2019 | |
| Covis Pharma Gmbh | $96.72 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $75.32 | 2022 | |
| Genentech, INC. | $52.46 | 2021-2025 | Xolair |
| Kedrion Biopharma, INC. | $47.79 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Cycle Pharmaceuticals INC | $46.15 | 2025 | Sajazir |
| Octapharma USA, INC. | $45.67 | 2021-2023 | Cutaquig |
| Verona Pharma, INC. | $34.54 | 2025 | Ohtuvayre |
| Leo Pharma INC. | $32.33 | 2022 | |
| Seqirus USA INC | $26.97 | 2025 | Fluad, Flucelvax |
| Ionis Pharmaceuticals, INC. | $23.27 | 2025 | |
| Mylan Specialty L.P. | $19.74 | 2023 | Yupelri |
| Bio Products Laboratory USA, INC. | $19.52 | 2022 | |
| Circassia INC. | $18.69 | 2019 | |
| Encore Dermatology INC. | $16.60 | 2020 | |
| X4 Pharmaceuticals, INC. | $15.32 | 2024 | Xolremdi |
| Uswm, LLC | $15.08 | 2021 | |
| Organon LLC | $11.50 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pallares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.